ATNAA Drug Patent Profile

Which patents cover Atnaa, and when can generic versions of Atnaa launch?

Atnaa is a drug marketed by Us Army and is included in one NDA.

The generic ingredient in ATNAA is atropine; pralidoxime chloride. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the atropine; pralidoxime chloride profile page.

Summary for ATNAA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Patent Applications:	589
DailyMed Link:	ATNAA at DailyMed

US Patents and Regulatory Information for ATNAA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Us Army	ATNAA	atropine; pralidoxime chloride	INJECTABLE;INTRAMUSCULAR	021175-001	Jan 17, 2002		DISCN	No	No

Last updated: April 23, 2026

ATNAA: Market Dynamics and Financial Trajectory

ATNAA’s commercial profile is not supportable from the available record. No validated identifiers, approvals, regulatory status, portfolio placement, or financial disclosures are provided for the drug “ATNAA.” Without those inputs, market size, pricing, channel mix, sales trajectory, payer adoption, competitive pressure, and revenue ramp assumptions cannot be calculated or evidenced.

What market dynamics apply to ATNAA?

No market-dynamics fact pattern can be produced because ATNAA cannot be uniquely mapped to an approved drug, an INN/brand name, a sponsor, a geography, or a mechanism-of-action from the supplied information.

What is ATNAA’s financial trajectory (sales, growth, or profitability)?

No financial trajectory can be produced because there is no linkage to audited revenue, prescription volume, price (WAC/NADAC/AMP), reimbursement outcomes, or payer/HTA coverage in the provided record.

What proof points should investors underwrite for ATNAA?

No proof points can be cited because the record does not include any of the following:

• Market authorization status (FDA/EMA and dates)
• Indication set (on-label uses and label scope)
• Country list and launch timeline
• Manufacturer/sponsor and investor filings
• Public sales, prescription, or utilization data
• Patent and exclusivity posture that drives the commercial window

Key Takeaways

• ATNAA cannot be analyzed for market dynamics or financial trajectory because it is not uniquely identifiable and no validated regulatory or financial data is provided.
• No evidence-backed conclusions on pricing, payer adoption, competitive dynamics, or revenue ramp can be generated from the current record.

FAQs

1. What is ATNAA’s regulatory status?
   Not determinable from the provided record.

2. Which indications does ATNAA have, and where is it marketed?
   Not determinable from the provided record.

3. What does ATNAA cost and how is it reimbursed?
   Not determinable from the provided record.

4. What are ATNAA sales and market share trends?
   Not determinable from the provided record.

5. How does patent life or exclusivity affect ATNAA’s commercial window?
   Not determinable from the provided record.

References

No sources provided in the record to cite.